# A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

> **NCT03574571** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 732 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Docetaxel 75 mg/m2
- **DRUG:** Docetaxel 60 mg/m2
- **DRUG:** Radium-223

## Key facts

- **NCT ID:** NCT03574571
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-06-19
- **Primary completion:** 2027-04-01
- **Final completion:** 2027-04-01
- **Target enrollment:** 732 (ACTUAL)
- **Last updated:** 2026-05-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03574571

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03574571, "A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer". Retrieved via AI Analytics 2026-09-15 from https://api.ai-analytics.org/clinical/NCT03574571. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*